SCHEMBL7125201

SCHEMBL7125201

Nc1ccc(Sc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
IKZF3 Q9UKT9 1/20 0.43
CHRNA7 P36544 1/20 0.43
EZH2 Q15910 1/20 0.39
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
POLB P06746 2/20 0.36
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
APEX1 P27695 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7124390 0.90 CHRNA7 (0.43) DDB1CRBNIKZF3CHRNA7EZH2
SCHEMBL7124385 0.89 CHRNA7 (0.44) CHRNA7EZH2SLC6A2SLC6A4SLC6A3
SCHEMBL7127524 0.89 CHRNA7 (0.55) CHRNA7EZH2MEN1KMT2AHTR3E
SCHEMBL7125274 0.89 CHRNA7 (0.43) DDB1CRBNIKZF3CHRNA7EZH2
SCHEMBL7116048 0.88 HPGD (0.46) CHRNA7EZH2SLC6A2SLC6A4SLC6A3
SCHEMBL7123508 0.88 TRPV1 (0.44) CHRNA7EZH2SLC6A4SLC6A3TSHR
SCHEMBL7115015 0.86 CA2 (0.42) CHRNA7CHRNB2CHRNA4
SCHEMBL7125131 0.86 EPHX2 (0.49) CHRNA7EZH2SLC6A2SLC6A4SLC6A3
SCHEMBL7124170 0.85 MMP2 (0.44) DDB1CRBNIKZF3EZH2POLB
SCHEMBL7125311 0.85 CHRNA7 (0.42) CHRNA7EZH2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 DDB1 1731/4885CRBN 1464/4885IKZF3 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.